Athersys subsidiary enters into research agreement with animal health company for cell therapy

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Cleveland biopharmaceutical company Athersys Inc. (NASDAQ:ATHX) is seeking to expand the market for its main stem cell product. Athersys announced Wednesday morning, Jan. 18, that it will work with a “global leader in the animal health business segment” to develop cell therapy technology for use in a “non-disclosed animal health area.

Click here to read the complete article.

Originally published January 18, 2017.